Clinical trial · no report yet · Phase 2
GeparNuevo
Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer
- NCT02685059 ↗
- Completed
- GBG Forschungs GmbH
- 22 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 10 | |
| YouTube | 9 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase II Study to Investigate the Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Containing Chemotherapy in Triple Negative Breast Cancer (GeparNuevo)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Breast Cancer
- Interventions
- MEDI4736 (Anti PD-L1); Placebo; nab-Paclitaxel; Epirubicin; Cyclophosphamide
- Arms
- MEDI4736 · Experimental
- Placebo · Placebo comparator
- Taxane · Active comparator
- Epirubicin · Active comparator
- Cyclophosphamide · Active comparator
- Enrollment
- 174
- Primary outcomes
- pathological complete response (pCR= ypT0 ypN0)
- Sponsor
- GBG Forschungs GmbH with AstraZeneca, Celgene
- Start
- Jun 2016
- Primary completion
- Mar 2018
- Results posted
- No
- Registry record
- NCT02685059 · updated Feb 15, 2021
Publications
linked from the registry- Loibl S, Untch M, Huober J, Schaser V, Braun M, Denkert C, Hartkopf A, Blohmer JU, Hanusch C, Link T, Reinisch M, Zahm DM, Weide R, Bjelic-Radisic V, Staib P, Tesch H, Rhiem K, Lorenz R, Rey J, Schneeweiss A. Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial. J Clin Oncol. 2026 Jun 10;44(17):1580-1586. doi: 10.1200/JCO-25-02311. Epub 2026 Apr 20. PubMed 42008768
- Massa C, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer JU, Zahm DM, Jackisch C, van Mackelenbergh M, Thomalla J, Marme F, Huober J, Muller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching PA, Untch M, Loibl S, Weber K, Seliger B. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. J Immunother Cancer. 2020 Nov;8(2):e001261. doi: 10.1136/jitc-2020-001261. PubMed 33199511
- Perez-Garcia J, Soberino J, Racca F, Gion M, Stradella A, Cortes J. Atezolizumab in the treatment of metastatic triple-negative breast cancer. Expert Opin Biol Ther. 2020 Sep;20(9):981-989. doi: 10.1080/14712598.2020.1769063. Epub 2020 May 25. PubMed 32450725
- Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kummel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019 Aug 1;30(8):1279-1288. doi: 10.1093/annonc/mdz158. PubMed 31095287